Zacks Research Comments on Dr. Reddy’s Laboratories Limited’s FY2026 Earnings (NYSE:RDY)

Dr. Reddy’s Laboratories Limited (NYSE:RDY) – Investment analysts at Zacks Research decreased their FY2026 earnings per share (EPS) estimates for Dr. Reddy’s Laboratories in a report released on Tuesday, April 16th. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of $4.11 for the year, down from their prior forecast of $4.12. The consensus estimate for Dr. Reddy’s Laboratories’ current full-year earnings is $3.96 per share.

Dr. Reddy’s Laboratories (NYSE:RDY) last posted its quarterly earnings data on Wednesday, January 31st. The company reported $0.99 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.11. The company had revenue of $867.00 million during the quarter, compared to analyst estimates of $827.81 million. Dr. Reddy’s Laboratories had a return on equity of 20.97% and a net margin of 19.26%.

Other equities research analysts have also issued research reports about the company. Jefferies Financial Group lowered Dr. Reddy’s Laboratories from a “buy” rating to an “underperform” rating in a research note on Thursday, January 11th. Barclays lifted their price objective on Dr. Reddy’s Laboratories from $75.00 to $80.00 and gave the company an “overweight” rating in a research note on Monday, January 29th. Finally, StockNews.com raised Dr. Reddy’s Laboratories from a “buy” rating to a “strong-buy” rating in a research note on Friday, April 5th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $80.00.

Dr. Reddy’s Laboratories Price Performance

NYSE:RDY opened at $70.92 on Wednesday. The firm has a market capitalization of $11.84 billion, a price-to-earnings ratio of 18.71, a P/E/G ratio of 1.79 and a beta of 0.58. Dr. Reddy’s Laboratories has a 52-week low of $53.12 and a 52-week high of $77.72. The stock has a fifty day moving average of $74.50 and a 200 day moving average of $70.17. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.90 and a current ratio of 2.55.

Institutional Investors Weigh In On Dr. Reddy’s Laboratories

Several hedge funds have recently added to or reduced their stakes in the company. Artemis Investment Management LLP bought a new stake in Dr. Reddy’s Laboratories during the first quarter worth about $594,000. Janiczek Wealth Management LLC lifted its stake in Dr. Reddy’s Laboratories by 39.2% during the first quarter. Janiczek Wealth Management LLC now owns 6,177 shares of the company’s stock worth $453,000 after purchasing an additional 1,740 shares during the last quarter. DGS Capital Management LLC lifted its stake in Dr. Reddy’s Laboratories by 15.2% during the first quarter. DGS Capital Management LLC now owns 9,922 shares of the company’s stock worth $728,000 after purchasing an additional 1,306 shares during the last quarter. Ballentine Partners LLC lifted its stake in Dr. Reddy’s Laboratories by 24.9% during the first quarter. Ballentine Partners LLC now owns 13,391 shares of the company’s stock worth $982,000 after purchasing an additional 2,666 shares during the last quarter. Finally, Contravisory Investment Management Inc. bought a new stake in Dr. Reddy’s Laboratories during the first quarter worth about $189,000. Institutional investors own 14.02% of the company’s stock.

About Dr. Reddy’s Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations.